专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20080058280A1 Treatment of Lymphoma Using 10-Propargyl-10-Deazaaminopterin and Gemcitabine 有权
标题翻译：使用10-炔丙基-10脱氮氨基蝶呤和吉西他滨治疗淋巴瘤
公开(公告)号：US20080058280A1
公开(公告)日：2008-03-06
申请号：US11568254
申请日：2005-05-31
申请人： Owen O'Connor , Francis Sirotnak
发明人： Owen O'Connor , Francis Sirotnak
IPC分类号： A61K31/7072 , A61K31/519
CPC分类号： A61K31/519 , A61K31/525 , A61K31/7068 , A61K2300/00
摘要： Lymphoma is treated using therapeutic combinations of PDX and gemcitabine by administering to a patient suffering from lymphoma a therapeutically effective amount of PDX in combination with a therapeutically effective amount of gemcitabine. The two agents can be administered together or in either order, although administration of PDX followed by gemcitabine is preferred. As in the case of MTX and Ara-C, synergism is observed, but the extent of the synergism is greater. Further, test results indicate that mechanism of action for combinations of PDX and Gem is different than for MTX and Ara-C, with more emphasis on induction of apoptosis.
摘要翻译：使用PDX和吉西他滨的治疗组合治疗淋巴瘤，其通过向患有淋巴瘤的患者施用治疗有效量的PDX与治疗有效量的吉西他滨组合治疗。两种药剂可以一起施用或以任一顺序施用，尽管优选施用PDX，然后是吉西他滨。如MTX和Ara-C的情况，观察到协同作用，但协同作用的程度更大。此外，测试结果表明，PDX和Gem组合的作用机理与MTX和Ara-C不同，更强调凋亡诱导。

82. 发明申请

US20070148662A1 Prostate-specific membrane antigen 审中-公开
标题翻译：前列腺特异性膜抗原
公开(公告)号：US20070148662A1
公开(公告)日：2007-06-28
申请号：US11480319
申请日：2006-06-30
申请人： Ron Israeli , Warren Heston , William Fair
发明人： Ron Israeli , Warren Heston , William Fair
IPC分类号： C12Q1/68 , G01N33/574 , C07H21/04 , C12P21/06 , C07K14/705
CPC分类号： C07K14/4748 , A61K39/00 , C07K14/705 , C12Q1/6883 , C12Q2600/158 , G01N2800/342
摘要： This invention provides an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention also provides prostate-specific membrane nucleic acid of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention further provides vector and vector host expression system for the prostate-specific membrane antigen. This invention also provides methods to identify ligands which bind to the prostate-specific membrane antigen, to generate antibody against a complete prostate-specific membrane antigen or a portion of the antigen. This invention further provides purified prostate-specific membrane antigen. This invention provides a therapeutic agent comprising an antibody directed against to prostate-specific membrane antigen and a cytotoxic agent conjugated thereto. This invention also provides a method of imaging prostate cancer and an immunoassay for measuring the amount of the prostate-specific membrane antigen in a biological simple. This invention further provides transgenic nonhuman mammal which comprises the isolated nucleic acid molecule encoding a mammalian prostate-specific membrane antigen.
摘要翻译：本发明提供了编码哺乳动物前列腺特异性膜抗原的分离的哺乳动物核酸分子。本发明还提供能够与编码哺乳动物前列腺特异性膜抗原的核酸分子的序列特异性杂交的至少15个核苷酸的前列腺特异性膜核酸。本发明进一步提供前列腺特异性膜抗原的载体和载体宿主表达系统。本发明还提供了鉴定与前列腺特异性膜抗原结合的配体的生成抗体以产生针对完整的前列腺特异性膜抗原或部分抗原的抗体的方法。本发明还提供了纯化的前列腺特异性膜抗原。本发明提供一种治疗剂，其包含针对前列腺特异性膜抗原的抗体和与其缀合的细胞毒性剂。本发明还提供了一种成像前列腺癌的方法和用于测量生物学简单的前列腺特异性膜抗原的量的免疫测定法。本发明还提供了转基因非人哺乳动物，其包含编码哺乳动物前列腺特异性膜抗原的分离的核酸分子。

83. 发明授权

US07122359B2 Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars 有权
标题翻译：核苷酸转移酶的活性位点工程和合成天然和“非天然”UDP-和TDP-核苷酸糖的一般酶法
公开(公告)号：US07122359B2
公开(公告)日：2006-10-17
申请号：US10013542
申请日：2001-12-13
申请人： Jon Thorson , Dimitar B. Nikilov
发明人： Jon Thorson , Dimitar B. Nikilov
IPC分类号： C12N9/10 , C12N15/00
CPC分类号： C07H11/04 , C07H15/24 , C07H15/252 , C07H17/00 , C07H17/08 , C07H19/10 , C07H19/207 , C12N9/1241 , C40B40/00
摘要： The present invention provides mutant nucleotidylyl-transferases, such as Ep, having altered substrate specificity; methods for their production; and methods of producing nucleotide sugars, which utilize these nucleotidylyl-transferases. The present invention also provides methods of synthesizing desired nucleotide sugars using natural and/or modified Ep or other nucleotidyltransferases; and nucleotide sugars sythesized by the present methods. The present invention further provides new glycosyl phosphates, and methods for making them.
摘要翻译：本发明提供具有改变的底物特异性的突变体核苷酸转移酶，例如Eβ; 生产方法; 以及使用这些核苷酸转移酶的产生核苷酸糖的方法。本发明还提供了使用天然和/或修饰的Ep或其它核苷酸转移酶合成所需核苷酸糖的方法; 和通过本发明方法合成的核苷酸糖。本发明还提供了新的糖基磷酸酯及其制备方法。

84. 发明申请

US20060134642A1 Pharmacological targeting of bacterial DNA ligase for treatment and prevention of bacterial infections 审中-公开
标题翻译：细菌DNA连接酶的药理学靶向用于治疗和预防细菌感染
公开(公告)号：US20060134642A1
公开(公告)日：2006-06-22
申请号：US10935291
申请日：2004-09-07
申请人： Stewart Shuman , Verl Sriskanda
发明人： Stewart Shuman , Verl Sriskanda
IPC分类号： C12Q1/68 , C07H21/04 , C12N9/06 , C12N15/74 , C12N1/21
CPC分类号： C12N9/93
摘要： This invention provides methods for the discovery of molecules that target an essential step of bacterial DNA replication—the sealing of DNA strands by NAD+-dependent DNA ligase. Specific structural components of NAD+-dependent DNA ligase that are important for the reaction of DNA ligase with NAD+ and that comprise a putative binding site for the NMN component of NAD+ were identified. The invention also includes recombinant DNA ligase enzymes that are defective in their reaction with NAD+, but active in the ligation of pre-adenylated DNA nicks. An underlying principle of this invention is the use of NAD+-reactive and NAD+-defective ligases to identify molecules that specifically bind to the NAD+-binding site of DNA ligase and thereby interfere with the reaction of DNA ligase with NAD+.
摘要翻译：本发明提供了发现靶向细菌DNA复制的必需步骤的分子的方法 - 通过NAD +依赖性DNA连接酶密封DNA链。对DNA连接酶与NAD +的反应重要的NAD + / - 依赖性DNA连接酶的特异性结构组分，其包含NMNA NMNA成分的推定结合位点， SUP> + 。本发明还包括与NAD + +反应有缺陷的重组DNA连接酶，但在腺苷酸化DNA缺口连接中是有活性的。本发明的基本原理是使用NAD +反应性和NAD + - 有效连接酶来鉴定特异性结合NAD + / SUP- DNA连接酶的结合位点，从而干扰DNA连接酶与NAD +的反应。

85. 发明授权

US07045495B2 Combination of bryostatin and paclitaxel for treating cancer 失效
公开(公告)号：US07045495B2
公开(公告)日：2006-05-16
申请号：US10215178
申请日：2002-08-07
申请人： Gary K. Schwartz , Anthony P. Albino
发明人： Gary K. Schwartz , Anthony P. Albino
IPC分类号： A01N61/00
CPC分类号： G01N33/5011 , A61K49/0004
摘要： This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

86. 发明授权

US07014856B1 Ganglioside-KLH conjugate vaccines plus OS-21 失效
标题翻译：神经节苷脂 - KLH结合疫苗加OS-21
公开(公告)号：US07014856B1
公开(公告)日：2006-03-21
申请号：US08196154
申请日：1994-01-21
申请人： Philip Ordway Livingston , Friedhelm Helling
发明人： Philip Ordway Livingston , Friedhelm Helling
IPC分类号： A61K39/385 , A61K39/39
CPC分类号： A61K39/0011 , A61K31/70 , A61K47/646 , A61K2039/55577 , A61K2039/57 , A61K2039/6081
摘要： This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.
摘要翻译：本发明提供了用于刺激或增强疫苗所用受试者的疫苗，产生识别神经节苷脂的抗体，其包含与有效刺激或增强抗体产生的免疫原性蛋白质结合的量的神经节苷脂或寡糖部分受试者，有效量的佐剂和药学上可接受的载体。

87. 发明授权

US07001601B1 Ganglioside-KLH conjugate vaccine plus QS-21 失效
标题翻译：神经节苷脂KLH偶联疫苗加QS-21
公开(公告)号：US07001601B1
公开(公告)日：2006-02-21
申请号：US08477147
申请日：1995-06-07
申请人： Philip Ordway Livingston , Friedhelm Helling
发明人： Philip Ordway Livingston , Friedhelm Helling
IPC分类号： A61K39/385 , A61K39/39
CPC分类号： A61K39/0011 , A61K31/70 , A61K47/646 , A61K2039/55577 , A61K2039/57 , A61K2039/6081
摘要： This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.
摘要翻译：本发明提供了用于刺激或增强疫苗所用受试者的疫苗，产生识别神经节苷脂的抗体，其包含与有效刺激或增强抗体产生的免疫原性蛋白质结合的量的神经节苷脂或寡糖部分受试者，有效量的佐剂和药学上可接受的载体。

88. 发明授权

US06989383B1 Method of treating cancer 失效
标题翻译：癌症治疗方法
公开(公告)号：US06989383B1
公开(公告)日：2006-01-24
申请号：US09445054
申请日：1998-06-04
申请人： Neal Rosen , Laura Sepp-Lorenzino , Mark M. Moasser , Allen I. Oliff , Jackson B. Gibbs , Nancy Kohl , Samuel L. Graham , George C. Prendergast
发明人： Neal Rosen , Laura Sepp-Lorenzino , Mark M. Moasser , Allen I. Oliff , Jackson B. Gibbs , Nancy Kohl , Samuel L. Graham , George C. Prendergast
IPC分类号： A61K31/495 , A61K31/50 , A61K31/335 , A61K31/35 , A61K31/34
CPC分类号： A61K31/415 , A61K31/495 , A61K41/00 , A61K45/06
摘要： The present invention relates to methods of treating cancer using a combination of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at lest two therapeutic agents selected from a group consisting of a compound which is an antineoplastic agent and a compound which is an inhibitor or prenyl-protein transferase. The invention also relates to methods of preparing such compositions.
摘要翻译：本发明涉及使用抗肿瘤剂化合物和作为异戊烯基 - 蛋白转移酶抑制剂的化合物的组合来治疗癌症的方法，该方法包括以任何顺序依次或同时向所述哺乳动物施用量至少两种选自由抗肿瘤剂的化合物和作为抑制剂或异戊烯基 - 蛋白质转移酶的化合物组成的组的治疗剂。本发明还涉及制备这种组合物的方法。

89. 发明授权

US06967022B1 Ganglioside-KLH conjugate vaccines plus QS-21 失效
公开(公告)号：US06967022B1
公开(公告)日：2005-11-22
申请号：US08475784
申请日：1995-06-07
申请人： Philip Ordway Livingston , Friedhelm Helling
发明人： Philip Ordway Livingston , Friedhelm Helling
IPC分类号： A61K45/00 , A61K31/70 , A61K39/00 , A61K45/08 , A61K47/48 , A61P35/00 , A61K39/385 , A61K39/39
CPC分类号： A61K39/0011 , A61K31/70 , A61K47/646 , A61K2039/55577 , A61K2039/57 , A61K2039/6081
摘要： This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.

90. 发明授权

US06946456B2 Methods for treating cell proliferative disorders and viral infections 有权
标题翻译：治疗细胞增殖障碍和病毒感染的方法
公开(公告)号：US06946456B2
公开(公告)日：2005-09-20
申请号：US10343246
申请日：2001-07-27
申请人： Neal Rosen , Mary Srethapakdi
发明人： Neal Rosen , Mary Srethapakdi
IPC分类号： C07D225/06 , A61K31/33 , A61K31/335 , A61K31/336 , A61K31/395 , A61K45/00 , A61K48/00 , A61P31/12 , A61P31/14 , A61P35/00 , A61P43/00 , C07D493/04
CPC分类号： A61K31/33 , A61K31/336 , A61K31/395 , A61K48/00
摘要： The present invention concerns methods for treating cell proliferative diseases, tumors associated with viral infections, and certain viral infections. The disclosed methods use compounds which inhibit heat shock protein 90 proteins. Such methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction.
摘要翻译：本发明涉及治疗细胞增殖性疾病，与病毒感染相关的肿瘤和某些病毒感染的方法。所公开的方法使用抑制热休克蛋白90蛋白质的化合物。这种方法阻止Rb细胞在细胞周期的G2 / M期的负面或缺陷，并迅速导致其破坏。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式